

BAFIERTAM (monomethyl fumarate), VUMERITY (diroximel fumarate)

Preferred product: generic dimethyl fumarate.

*Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.

Pre - PA Allowance

None

Prior - Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Relapsing Multiple Sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

AND ALL of the following:

- 1. Recent CBC (within 6 months) before initiation
 - a. Baseline lymphocyte count must be obtained and monitored annually
- 2. NO active serious infections, or
 - a. If present, treatment will be held until resolved
- 3. Monitor for the signs and symptoms of progressive multifocal leukoencephalopathy (PML) and discontinue if present
- 4. **NOT** to be used with other disease modifying medications for MS
- 5. **NOT** given concurrently with live vaccines
- Bafiertam and Vumerity ONLY: Patient MUST have tried dimethyl fumarate (generic Tecfidera) AND ONE of the other preferred MS medications (see Appendix 1) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

Prior - Approval Limits

Quantity

Medication	Quantity Limit
Bafiertam	95 mg capsules – 360 capsules per 90 days OR



BAFIERTAM (monomethyl fumarate), VUMERITY (diroximel fumarate)

Preferred product: generic dimethyl fumarate.

*Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.

dimethyl fumarate	120 mg capsules – 14 day (starter pack) AND
(generic Tecfidera)	240 mg capsules – 180 capsules per 90 days OR
Vumerity	231 mg capsules – 360 capsules per 90 days

Medication with Approved Formulary Exception ONLY	Quantity Limit
Tecfidera brand	120 mg capsules – 14 day (starter pack) AND 240 mg capsules – 180 capsules per 90 days

Duration 12 months

Prior – Approval Renewal Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Relapsing Multiple Sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

AND ALL of the following:

- 1. Lymphocyte count must be monitored annually
- 2. NO active serious infections, or
 - a. If present, treatment will be held until resolved
- 3. Continue to monitor for signs and symptoms of PML and discontinue if present
- 4. **NOT** to be used with other disease modifying medications for MS
- 5. **NOT** given concurrently with live vaccines
- Bafiertam and Vumerity ONLY: Patient MUST have tried dimethyl fumarate (generic Tecfidera) AND ONE of the other preferred MS medications (see Appendix 1) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)



BAFIERTAM (monomethyl fumarate), VUMERITY (diroximel fumarate)

Preferred product: generic dimethyl fumarate.

*Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.

Prior - Approval Renewal Limits

Quantity

Medication	Quantity Limit
Bafiertam	95 mg capsules – 360 capsules per 90 days OR
dimethyl fumarate	240 mg capsules – 180 capsules per 90 days OR
(generic Tecfidera) Vumerity	231 mg capsules – 360 capsules per 90 days

Medication with Approved Formulary Exception ONLY	Quantity Limit
Tecfidera brand	240 mg capsules – 180 capsules per 90 days

Duration 12 months



BAFIERTAM (monomethyl fumarate), VUMERITY (diroximel fumarate)

Preferred product: generic dimethyl fumarate.

*Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.

Appendix 1 - List of Preferred Multiple Sclerosis (MS) Medications

Medication Name	Route of Administration
dimethyl fumarate* (generic Tecfidera) *must try this drug plus one other preferred MS medication oral or injectable	Oral
fingolimod (generic Gilenya)	Oral**
Mayzent	Oral**
teriflunomide (generic Aubagio)	Oral**
Zeposia	Oral**

^{**} indicates separate criteria will need to be met

Medication Name	Route of Administration
Avonex	Injectable
Betaseron	Injectable
glatiramer acetate (generic Copaxone)	Injectable
Glatopa	Injectable
Plegridy	Injectable
Rebif	Injectable